PERTINENT FINDINGS: [89Zr]GPC1 mAb PET showed high tumoral uptake in the early phase after administration, whereas targeted α-therapy using [211At]GPC1 mAb successfully suppressed tumor growth. Here, GPC1 is linked to neoplasm.